Cytosorbents Corp (OQ:CTSO)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 305 COLLEGE ROAD EAST
PRINCETON NJ 08540
Tel: N/A
Website: https://cytosorbents.com
IR: See website
<
Key People
Vincent J. Capponi
President, Chief Operating Officer 		Phillip P. Chan
Chief Executive Officer, Director 		Kathleen P. Bloch
Chief Financial Officer
Efthymios N. Deliargyris
Chief Medical Officer 		   
Business Overview
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company's flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
Financial Overview
For the fiscal year ended 31 December 2023, Cytosorbents Corp revenues increased 5% to $36.3M. Net loss decreased 13% to $28.5M. Revenues reflect CytoSorb sales increase of 9% to $31M. Lower net loss reflects Foreign Exchange Gain/Loss'��Non-Business increase from $2.4M (expense) to $1.9M (income), Advertising Expenses decrease of 57% to $253K (expense), Selling, general and administrative - Ba decrease of 1% to $30M (expense).
Employees: 186 as of Mar 7, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $32.16M as of Dec 31, 2023
Annual revenue (TTM): $36.35M as of Dec 31, 2023
EBITDA (TTM): -$28.81M as of Dec 31, 2023
Net annual income (TTM): -$28.51M as of Dec 31, 2023
Free cash flow (TTM): -$22.59M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 54,240,265 as of Dec 31, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More